Most cited papers from Symphogen (Denmark)

Symphogen (Denmark)

What are the most cited papers from Symphogen (Denmark)?

The most cited paper from Symphogen (Denmark) is "Novel antibody–antibiotic conjugate eliminates intracellular S. aureus" (Sophie M. Lehar et al., 2015), with 851 citations. Next come "The genomic landscape of response to EGFR blockade in colorectal cancer" (500) and "Targeting the ERBB family in cancer: couples therapy" (470).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 29 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Novel antibody–antibiotic conjugate eliminates intracellular S. aureus Sophie M. Lehar et al. · Nature	Nov 2015	851
2	The genomic landscape of response to EGFR blockade in colorectal cancer Andrea Bertotti et al. · Nature Open access	29 Sep 2015	500
3	Targeting the ERBB family in cancer: couples therapy Niall Christopher Tebbutt, Mikkel Wandahl Pedersen, Terrance G. Johns · Nature reviews. Cancer Review	16 Aug 2013	470
4	Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog Hanne Borger Rasmussen, Sven Branner, Finn C. Wiberg et al. · Nature Structural Biology	16 Dec 2002	426
5	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018 Manisha H. Shah et al. · Journal of the National Comprehensive Cancer Network Open access	Jun 2018	393
6	The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors Erik A. Nelson, Sarah R. Walker, Ellen Weisberg et al. · Blood Open access	14 Jan 2011	280
7	Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Klaus Koefoed et al. · Cancer Research	12 Jan 2010	227
8	Amino acid and glucose metabolism in fed‐batch CHO cell culture affects antibody production and glycosylation Yuzhou Fan, Ioscani Jiménez del Val, Christian R. Müller et al. · Biotechnology and Bioengineering	12 Sep 2014	221
9	DNA unzipped under a constant force exhibits multiple metastable intermediates Claudia Danilowicz, Vincent W. Coljee, Cédric Bouzigues et al. · Proceedings of the National Academy of Sciences Open access	6 Feb 2003	171
10	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses Clara O. Montagut et al. · JAMA Oncology Open access	8 Feb 2018	145
11	Isolation of Human Antibody Repertoires with Preservation of the Natural Heavy and Light Chain Pairing Per‐Johan Meijer, Peter Sejer Andersen, Margit Haahr Hansen et al. · Journal of Molecular Biology	3 Mar 2006	126
12	Fluorophore labeling of a cell-penetrating peptide significantly alters the mode and degree of biomembrane interaction Sofie Fogh Hedegaard, Mohammed Sobhi Derbas, Tania Kjellerup Lind et al. · Scientific Reports Open access	16 Apr 2018	118
13	CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models Lotte K. Kristensen, Camilla Fröhlich, Camilla Laulund Christensen et al. · Theranostics Open access	2019	109
14	Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor Klaus Koefoed, Lucilla Steinaa, Josefine Nielsen Søderberg et al. · mAbs Open access	Nov 2011	93
15	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype Barbara Lupo et al. · Science Translational Medicine Open access	5 Aug 2020	87
16	Production of target‐specific recombinant human polyclonal antibodies in mammalian cells Finn C. Wiberg, Søren K. Rasmussen, Torben P. Frandsen et al. · Biotechnology and Bioengineering	4 Apr 2006	87
17	Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity Helle Jane Jacobsen, Thomas T. Poulsen, Anna Dahlman et al. · Clinical Cancer Research	23 Apr 2015	87
18	Novel Staphylococcal Glycosyltransferases SdgA and SdgB Mediate Immunogenicity and Protection of Virulence-Associated Cell Wall Proteins Wouter L. W. Hazenbos et al. · PLoS Pathogens Open access	10 Oct 2013	86
19	The role of dendritic cells in cancer Morten Hansen, Mads Hald Andersen · Seminars in Immunopathology	16 Sep 2016	85
20	Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab Mari Iida, Toni Michel Brand, Megan M. Starr et al. · Neoplasia Open access	Oct 2013	82
21	Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses against Tetanus Toxoid Tine Rugh Poulsen, Per‐Johan Meijer, Allan D. Jensen et al. · The Journal of Immunology	Sep 2007	80
22	Limits for Antibody Affinity Maturation and Repertoire Diversification in Hypervaccinated Humans Tine Rugh Poulsen, Allan D. Jensen, John Sørensen Haurum et al. · The Journal of Immunology	20 Sep 2011	79
23	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero et al. · Cancer Discovery	11 May 2015	78
24	Inter-laboratory study of an optimised peptide mapping workflow using automated trypsin digestion for monitoring monoclonal antibody product quality attributes Silvia Millán‐Martín, Craig Jakes, Sara Carillo et al. · Analytical and Bioanalytical Chemistry Open access	25 Jul 2020	77
25	Recombinant polyclonal antibodies: the next generation of antibody therapeutics? John Sørensen Haurum · Drug Discovery Today	21 Jun 2006	69
26	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer Francisco Javier Sánchez-Martín et al. · Clinical Cancer Research	17 Feb 2016	68
27	Recombinant protein expression by targeting pre-selected chromosomal loci Kristina Nehlsen, Roland Schucht, Leonor Gama-Norton et al. · BMC Biotechnology Open access	Dec 2009	68
28	A multi‐pronged investigation into the effect of glucose starvation and culture duration on fed‐batch CHO cell culture Yuzhou Fan, Ioscani Jiménez del Val, Christian R. Müller et al. · Biotechnology and Bioengineering Open access	20 Apr 2015	67
29	Directed evolution of a maltogenic α-amylase from Bacillus sp. TS-25 A. Daniel Jones, Michael H. Lamsa, Torben P. Frandsen et al. · Journal of Biotechnology	8 Feb 2008	65
30	Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework Ioscani Jiménez del Val, Yuzhou Fan, Dietmar Weilguny · Biotechnology Journal Open access	8 Jan 2016	64
31	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia Tadeusz Robak et al. · Blood	21 Aug 2012	55
32	Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Klaus Koefoed et al. · Molecular Cancer Therapeutics	23 Jan 2015	54
33	HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer Aïda Sampera, Francisco Javier Sánchez-Martín, Oriol Arpí et al. · Molecular Cancer Therapeutics	4 Sep 2019	52
34	Glycoprofiling effects of media additives on IgG produced by CHO cells in fed‐batch bioreactors Helene Faustrup Kildegaard, Yuzhou Fan, Jette Wagtberg Sen et al. · Biotechnology and Bioengineering	29 Jul 2015	52
35	Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors Thomas T. Poulsen, Michael Monrad Grandal, Niels Jørgen Østergaard Skartved et al. · Clinical Cancer Research	5 Jul 2017	49
36	Recombinant antibody mixtures: Production strategies and cost considerations Søren K. Rasmussen, Henrik Næsted, Christian D. Muller et al. · Archives of Biochemistry and Biophysics	20 Jul 2012	48
37	Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab Mari Iida, Harsh Bahrar, Toni Michel Brand et al. · Molecular Cancer Therapeutics Open access	15 Jul 2016	45
38	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression Luis Jesus Schwarz, Katherine E. Hutchinson, Brent Neil Rexer et al. · JNCI Journal of the National Cancer Institute Open access	16 Mar 2017	44
39	Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity Göran Forsberg, Niels-Jörgen Skartved, Marie Wallén‐Öhman et al. · Journal of Immunotherapy	12 May 2010	44
40	A combination of two antibodies recognizing non‐overlapping epitopes of HER 2 induces kinase activity‐dependent internalization of HER 2 Monika Szymańska, Anne Marthe Fosdahl, Filip Nikolaysen et al. · Journal of Cellular and Molecular Medicine Open access	28 Jul 2016	43
41	Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use Torben P. Frandsen, Henrik Næsted, Søren K. Rasmussen et al. · Biotechnology and Bioengineering	14 Apr 2011	43
42	Syncytin-1 in differentiating human myoblasts: relationship to caveolin-3 and myogenin Bolette Bjerregard, Iwona Ziomkiewicz, Alexander Schulz et al. · Cell and Tissue Research	5 Jun 2014	43
43	Capturing the Natural Diversity of the Human Antibody Response against Vaccinia Virus Johan Lantto, Margit Haahr Hansen, Søren Kofoed Rasmussen et al. · Journal of Virology Open access	9 Dec 2010	41
44	Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen et al. · Clinical Cancer Research	9 Aug 2011	41
45	Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections Søren Bregenholt, Allan D. Jensen, Johan Lantto et al. · Current Pharmaceutical Design	30 May 2006	39
46	Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitor Hyun Jeong Kim, Sun Kyoung Kang, Woo Sun Kwon et al. · International Journal of Cancer Open access	13 Feb 2018	36
47	Structural, Energetic, and Functional Analysis of a Protein-Protein Interface at Distinct Stages of Affinity Maturation Eric J. Sundberg, Peter Sejer Andersen, Patrick M. Schlievert et al. · Structure Open access	Sep 2003	36
48	Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation Sylwia Jones, Peter King, Costin N. Antonescu et al. · Scientific Reports Open access	20 Jan 2020	35
49	Minor Structural Changes in a Mutated Human Melanoma Antigen Correspond to Dramatically Enhanced Stimulation of a CD4+ Tumor-infiltrating Lymphocyte Line Eric J. Sundberg, Mark W. Sawicki, Scott Southwood et al. · Journal of Molecular Biology	May 2002	35
50	Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models David Mark Francis, Shyhmin Huang, Eric A. Armstrong et al. · Clinical Cancer Research	29 Sep 2015	33

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.